KDM1A and acute myeloid leukemia: While usually not active in this non‐APL AML, LSD1 inhibition has also sensitized AML cells to the effect of All‐Trans Retinoic Acid (ATRA), suggesting the use of LSD1 inhibition as a combination treatment.